Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Virbac SA (GB:0NM7)
LSE:0NM7
Holding GB:0NM7?
Track your performance easily
0NM7 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€280.50 - €399.00
Previous Close€318
Volume207.00
Average Volume (3M)2.06K
Market Cap
€2.68B
Enterprise Value€2.65B
Total Cash (Recent Filing)€175.81M
Total Debt (Recent Filing)€148.38M
Price to Earnings (P/E)18.9
Beta0.83
Next Earnings
Mar 24, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jun 25, 2024Dividend Yield0.41%
Share Statistics
EPS (TTM)16.82
Shares OutstandingN/A
10 Day Avg. Volume2,238
30 Day Avg. Volume2,061
Standard Deviation0.10
R-Squared0.27
Alpha0.00925
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)2.24
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€383.33Price Target Upside20.54% Upside
Rating ConsensusHold
Number of Analyst Covering3
Virbac SA News
Bulls Say, Bears Say
Bulls Say
Emerging Markets GrowthExposures to emerging countries like India and Mexico are enabling an acceleration in the group's growth pace as the growing middle class in these countries and their purchasing power are fuelling the animal health sector.
Financial PerformanceVirbac’s 1H24 results were strong, with adjusted EBIT growth of +37% and a 21.4% operating margin.
Market OpportunityThe group historically slightly outperformed the global animal health industry where it has a small market share which provides an opportunity to keep growing at a solid pace.
Bears Say
Earnings GuidanceThe confirmed FY24 guidance implies limited 2H24 organic revenue growth of 2-3% and a -5% year-over-year adjusted EBIT decline.
Economic EnvironmentConcerns exist about the economic environment as the group embarks on a major investment programme and searches for a new CEO, making it premature to turn more positive currently.
Leadership UncertaintyThe fact that the company is actively searching for a new CEO makes analysts somewhat uncomfortable looking beyond 2025.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
5.63% Mutual Funds
― Other Institutional Investors
91.57% Public Companies and
Individual Investors
0NM7 FAQ
What was Virbac SA’s price range in the past 12 months?
Virbac SA lowest share price was €280.50 and its highest was €399.00 in the past 12 months.
What is Virbac SA’s market cap?
Currently, no data Available
When is Virbac SA’s upcoming earnings report date?
Virbac SA’s upcoming earnings report date is Mar 24, 2025 which is in 122 days.
How were Virbac SA’s earnings last quarter?
Virbac SA released its earnings results on Sep 13, 2024. The company reported €11.29 earnings per share for the quarter, beating the consensus estimate of N/A by €11.29.
Is Virbac SA overvalued?
According to Wall Street analysts Virbac SA’s price is currently Undervalued.
Does Virbac SA pay dividends?
Virbac SA pays a Annually dividend of €1.32 which represents an annual dividend yield of 0.41%. See more information on Virbac SA dividends here
What is Virbac SA’s EPS estimate?
Virbac SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Virbac SA have?
Virbac SA has 8,390,660 shares outstanding.
What happened to Virbac SA’s price movement after its last earnings report?
Virbac SA reported an EPS of €11.29 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.138%.
Which hedge fund is a major shareholder of Virbac SA?
Currently, no hedge funds are holding shares in GB:0NM7
---
Virbac SA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.61%
12-Months-Change
Fundamentals
Return on Equity
14.89%
Trailing 12-Months
Asset Growth
26.44%
Trailing 12-Months
Company Description
Virbac SA
Virbac SA is a major drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, followed by North America and Latin America. Most of the company's sales are generated from its Companion Animals segment, followed by its Food Producing Animals segment. Veterinarians remain Virbac's main client, yet the company's clients are particularly diverse throughout the world in terms of profession, size and expectations. Virbac's strategy focuses on dominating niche markets while either avoiding or remaining differentiated within the more competitive markets.
---
0NM7 Stock 12 Month Forecast
Average Price Target
€383.33
▲(20.54% Upside)
Technical Analysis
---